172 related articles for article (PubMed ID: 21460180)
41. The c-Myc-regulated lncRNA NEAT1 and paraspeckles modulate imatinib-induced apoptosis in CML cells.
Zeng C; Liu S; Lu S; Yu X; Lai J; Wu Y; Chen S; Wang L; Yu Z; Luo G; Li Y
Mol Cancer; 2018 Aug; 17(1):130. PubMed ID: 30153828
[TBL] [Abstract][Full Text] [Related]
42. BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.
Sharma N; Magistroni V; Piazza R; Citterio S; Mezzatesta C; Khandelwal P; Pirola A; Gambacorti-Passerini C
Mol Cancer; 2015 Jul; 14():132. PubMed ID: 26179066
[TBL] [Abstract][Full Text] [Related]
43. Cotylenin A and tyrosine kinase inhibitors synergistically inhibit the growth of chronic myeloid leukemia cells.
Ikejiri F; Honma Y; Okada T; Urano T; Suzumiya J
Int J Oncol; 2018 Jun; 52(6):2061-2068. PubMed ID: 29620253
[TBL] [Abstract][Full Text] [Related]
44. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia.
Roman-Gomez J; Jimenez-Velasco A; Agirre X; Cervantes F; Sanchez J; Garate L; Barrios M; Castillejo JA; Navarro G; Colomer D; Prosper F; Heiniger A; Torres A
Oncogene; 2005 Nov; 24(48):7213-23. PubMed ID: 16170379
[TBL] [Abstract][Full Text] [Related]
45. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate.
Boissel N; Rousselot P; Raffoux E; Cayuela JM; Maarek O; Charron D; Degos L; Dombret H; Toubert A; Rea D
Leukemia; 2004 Oct; 18(10):1656-61. PubMed ID: 15343347
[TBL] [Abstract][Full Text] [Related]
46. Phosphorylated Crkl reduction levels are associated with the lowest P-glycoprotein activity levels in cells from chronic myeloid leukemia patients.
Vasconcelos FC; Nestal de Moraes G; Moellmann-Coelho A; Maia RC
Leuk Res; 2013 Dec; 37(12):1711-8. PubMed ID: 24210993
[TBL] [Abstract][Full Text] [Related]
47. Expression of multidrug resistance 1 gene in association with CXCL12 in chronic myelogenous leukaemia.
Onishi I; Nakagawa Y; Murayama T; Hidaka M; Yamamoto K; Abe-Suzuki S; Abe S; Kurata M; Kitagawa M
Pathology; 2014 Dec; 46(7):623-9. PubMed ID: 25393253
[TBL] [Abstract][Full Text] [Related]
48. Novel agent nitidine chloride induces erythroid differentiation and apoptosis in CML cells through c-Myc-miRNAs axis.
Liu N; Li P; Zang S; Liu Q; Ma D; Sun X; Ji C
PLoS One; 2015; 10(2):e0116880. PubMed ID: 25647305
[TBL] [Abstract][Full Text] [Related]
49. Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.
Lucas CM; Harris RJ; Holcroft AK; Scott LJ; Carmell N; McDonald E; Polydoros F; Clark RE
Leukemia; 2015 Jul; 29(7):1514-23. PubMed ID: 25765543
[TBL] [Abstract][Full Text] [Related]
50. The proto-oncogene expression varies over the course of chronic myeloid leukemia.
Vidović A; Janković G; Colović M; Tomin D; Perunicić M; Bila J; Marković O; Bosković D
Hematology; 2008 Feb; 13(1):34-40. PubMed ID: 18534064
[TBL] [Abstract][Full Text] [Related]
51. Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?
Fitter S; Vandyke K; Schultz CG; White D; Hughes TP; Zannettino AC
J Clin Endocrinol Metab; 2010 Aug; 95(8):3763-7. PubMed ID: 20466781
[TBL] [Abstract][Full Text] [Related]
52. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells.
Venturini L; Battmer K; Castoldi M; Schultheis B; Hochhaus A; Muckenthaler MU; Ganser A; Eder M; Scherr M
Blood; 2007 May; 109(10):4399-405. PubMed ID: 17284533
[TBL] [Abstract][Full Text] [Related]
53. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence.
Takeishi S; Matsumoto A; Onoyama I; Naka K; Hirao A; Nakayama KI
Cancer Cell; 2013 Mar; 23(3):347-61. PubMed ID: 23518349
[TBL] [Abstract][Full Text] [Related]
54. Differential gene expression changes and their implication on the disease progression in patients with Chronic Myeloid Leukemia.
Chandran RK; Geetha N; Sakthivel KM; Kumar RS; Krishna KMNJ; Sreedharan H
Blood Cells Mol Dis; 2019 Jul; 77():51-60. PubMed ID: 30959263
[TBL] [Abstract][Full Text] [Related]
55. Long noncoding RNA HULC promotes cell proliferation by regulating PI3K/AKT signaling pathway in chronic myeloid leukemia.
Lu Y; Li Y; Chai X; Kang Q; Zhao P; Xiong J; Wang J
Gene; 2017 Apr; 607():41-46. PubMed ID: 28069548
[TBL] [Abstract][Full Text] [Related]
56. [The expression of C-myc oncogene in leukemia and its relationship to clinical symptoms].
Yang PM; Fu L
Zhonghua Nei Ke Za Zhi; 1992 Mar; 31(3):143-5, 187. PubMed ID: 1395924
[TBL] [Abstract][Full Text] [Related]
57. Role of ZNF224 in c-Myc repression and imatinib responsiveness in chronic myeloid leukemia.
Sodaro G; Cesaro E; Montano G; Blasio G; Fiorentino F; Romano S; Jacquel A; Aurberger P; Costanzo P
Oncotarget; 2018 Jan; 9(3):3417-3431. PubMed ID: 29423056
[TBL] [Abstract][Full Text] [Related]
58. PTBP2 exon 10 inclusion is associated with the progression of CML and it is BCR-ABL1 dependent.
Nandagopalan SR; Agatheeswaran S; Vadlamudi Y; Biswas S; Biswas G; Pattnayak NC; Chakraborty S
Int J Biochem Cell Biol; 2019 Apr; 109():69-75. PubMed ID: 30726713
[TBL] [Abstract][Full Text] [Related]
59. c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia.
Lucas CM; Harris RJ; Giannoudis A; Clark RE
Haematologica; 2015 May; 100(5):e179-82. PubMed ID: 25661443
[No Abstract] [Full Text] [Related]
60. Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival.
Guru SA; Sumi MP; Mir R; Beg MMA; Koner BC; Saxena A
BMC Cancer; 2022 Apr; 22(1):405. PubMed ID: 35421941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
